These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29057262)

  • 1. Relationship between Interferon Beta-1A Administration and Intracranial Vascular Tone Regulation in Patients with Relapsing-Remitting Multiple Sclerosis: A Pilot Study.
    Dattola V; Bonanno L; Naro A; Chillura A; Logiudice AL; Sessa E; Famà F; Quartarone A; Calabrò RS; Marino S; Russo M
    Biomed Res Int; 2017; 2017():5421416. PubMed ID: 29057262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis.
    Saida T; Kira J; Ueno Y; Harada N; Hirakata T
    Mult Scler Relat Disord; 2016 May; 7():102-8. PubMed ID: 27237769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis.
    Dupuy SL; Khalid F; Healy BC; Bakshi S; Neema M; Tauhid S; Bakshi R
    BMC Med Imaging; 2016 Oct; 16(1):56. PubMed ID: 27716096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.
    Kleinschnitz C; Niemczyk G; Rehberg-Weber K; Wernsdörfer C
    Int J Mol Sci; 2015 Jul; 16(7):15271-86. PubMed ID: 26154767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.
    Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP
    J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience.
    D'Amico E; Patti F; Zanghì A; Lo Fermo S; Chisari CG; Zappia M
    Expert Rev Clin Pharmacol; 2018 May; 11(5):531-536. PubMed ID: 29521113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Stable Multiple Sclerosis Patients Staying on Initial Interferon Beta Therapy Versus Switching to Another Interferon Beta Therapy: A US Claims Database Study.
    Cohan S; Smoot K; Kresa-Reahl K; Garland R; Yeh WS; Wu N; Watson C
    Adv Ther; 2018 Nov; 35(11):1894-1904. PubMed ID: 30341505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case report of thrombotic microangiopathy associated with subcutaneous interferon beta-1a: an emerging complication?
    Azkune Calle I; Sánchez Menoyo JL; Ruiz Ojeda J; García Moncó JC; Etxeguren Urkixo I
    Neurologia; 2016 Sep; 31(7):508-9. PubMed ID: 25449964
    [No Abstract]   [Full Text] [Related]  

  • 9. Early MRI results and odds of attaining 'no evidence of disease activity' status in MS patients treated with interferon β-1a in the EVIDENCE study.
    Coyle PK; Reder AT; Freedman MS; Fang J; Dangond F
    J Neurol Sci; 2017 Aug; 379():151-156. PubMed ID: 28716230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis.
    Liu Y; Vollmer T; Havrdova E; Riester K; Lee A; Phillips G; Wang P; Sabatella G
    Mult Scler Relat Disord; 2017 Jan; 11():18-24. PubMed ID: 28104250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study.
    Schwartzbach CJ; Grove RA; Brown R; Tompson D; Then Bergh F; Arnold DL
    J Neurol; 2017 Feb; 264(2):304-315. PubMed ID: 27888416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study.
    Freedman MS; Francis GS; Sanders EA; Rice GP; O'Connor P; Comi G; Duquette P; Metz L; Murray TJ; Bouchard JP; Abramsky O; Pelletier J; O'Brien F; ;
    Mult Scler; 2005 Feb; 11(1):41-5. PubMed ID: 15732265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™-the FUTURE study.
    Ghezzi A; Bianchi A; Baroncini D; Bertolotto A; Malucchi S; Bresciamorra V; Lanzillo R; Milani N; Martinelli V; Patti F; Chisari C; Rottoli M; Simone M; Paolicelli D; Visconti A;
    Neurol Sci; 2017 Nov; 38(11):1999-2005. PubMed ID: 28831635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.
    Fisher E; Nakamura K; Lee JC; You X; Sperling B; Rudick RA
    Mult Scler; 2016 Apr; 22(5):668-76. PubMed ID: 26238463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15.
    Kappos L; Kuhle J; Multanen J; Kremenchutzky M; Verdun di Cantogno E; Cornelisse P; Lehr L; Casset-Semanaz F; Issard D; Uitdehaag BM
    J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1202-7. PubMed ID: 26374702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
    Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
    Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis.
    Limmroth V; Malessa R; Zettl UK; Koehler J; Japp G; Haller P; Elias W; Obhof W; Viehöver A; Meier U; Brosig A; Hasford J; Putzki N; Kalski G; Wernsdörfer C;
    J Neurol; 2007 Jan; 254(1):67-77. PubMed ID: 17273808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L; Guo S; Kinter E; Fay M
    J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.